Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02348216 2024-06-04

ZUMA-1

Phase 1/2 Completed

307 enrolled 41 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02257567 2022-11-14

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

331 enrolled 81 charts 1 FDA

Lymphoid

Lymphoma

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, B-Cell

NCT01188681 2021-06-10

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Phase 1/2 Completed

79 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

91 enrolled 27 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1/2 Completed

55 enrolled 14 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01088984 2016-05-23

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Phase 1/2 Completed

43 enrolled 14 charts

Other hematologic neoplasm

Leukemia

NCT00920855 2012-10-04

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

40 enrolled 16 charts

Plasma cell

Multiple Myeloma

Clinical Trials

EPCORE™ NHL-2

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

ZUMA-1

FUSION NHL 001

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma